Live Breaking News & Updates on Genitourinary Oncology Disease Center

Stay updated with breaking news from Genitourinary oncology disease center. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Welireg Plus Cabometyx Shows Anti-Tumor Activity in Kidney Cancer Type

The Welireg-Cabometyx treatment combination demonstrated anti-tumor activity for some patients with clear cell renal carcinoma, according to a phase 2 trial.
....

United States , Dana Farber Cancer Institute , Tonik Choueiri , Database Consortium , Harvard Medical School , European Society For Medical Oncology , Genitourinary Oncology Disease Center , International Metastatic , International Metastatic Renal Cell Carcinoma Database Consortium , Lank Center , Medical Oncology , Annual Congress , Genitourinary Oncology , Kidney Cancer ,

Durable Antitumor Activity in ccRCC With Combination Belzutifan/Cabozantinib

“Belzutifan plus cabozantinib continue to show durable anti-tumor activity in patients with clear cell RCC who are treatment naïve or previously treated,” said Toni K. Choueiri, MD. ....

United States , Dana Farber Cancer Institute , France General , Nat Genet , Tonik Choueiri , Genitourinary Oncology Disease Center , European Society For Medical Oncology , Harvard Medical School , Lank Center , European Society Of Medical Oncology , International Metastatic , Database Consortium , Medical Oncology , Annual Congress , Genitourinary Oncology , European Society , Esmo 2023 , Clear Cell Rcc , Clear Cell Renal Carcinoma , Kidney Cancer ,

Belzutifan Plus Cabozantinib Delivers Durable Responses in ccRCC

Belzultifan in combination with cabozantinib generated durable responses independent of International Metastatic RCC Database Consortium risk category in patients with treatment-naïve clear cell renal cell carcinoma or those who had received prior immunotherapy. ....

United States , France General , Dana Farber Cancer Institute , Nat Genet , Belzultifan Welireg , Tonik Choueiri , Genitourinary Oncology Disease Center , Harvard Medical School , European Society Of Medical Oncology , International Metastatic , Database Consortium , Lank Center , Genitourinary Oncology , European Society , Medical Oncology , Belzultifan In Combination With Cabozantinib , Clear Cell Renal Carcinoma , Litespark 003 Trial ,